elapsed_time: 19s
was_input_captured: True
original_text: |
    FOR DOSE EXPANSION COHORT ONLY: Pathologically confirmed breast cancer with the following features:
    * Measurable disease by RECIST 1.1
    * ER and PR =< 1% by immunohistochemistry
    * Her-2/neu negative (0 or 1+ by immunohistochemistry OR not amplified by CAP/ASCO standards)
    * Metastatic or unresectable and locally advanced and not amenable to treatment with curative intent, in the opinion of the enrolling investigator
inclusion: True
